產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-RAPGEF2抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-RAPGEF2抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-RAPGEF2
Cat. Number:
Anti-RAPGEF2抗體KL-11581R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SummaryMembers of the RAS (see HRAS; MIM 190020) subfamily of GTPases function in signal transduction as GTP/GDP-regulated switches that cycle between inactive GDP- and active GTP-bound states. Guanine Anti-RAPGEF2抗體nucleotide exchange factors (GEFs), such as RAPGEF2, serve as RAS activators by promoting acquisition of GTP to maintain the active GTP-bound state and are the key link between cell surface receptors and RAS activation (Rebhun et al., 2000 [PubMed 10934204]).[supplied by OMIM, Mar 2008]
Also known as:
KIAA0313; Neural RAP guanine nucleotide exchange protein; nRap GEP; NRAPGEP; PDZ domain containing guanine Anti-RAPGEF2抗體nucleotide exchange factor 1; PDZ domain-containing guanine nucleotide exchange factor 1; PDZ GEF1; PDZ-GEF1; PDZGEF1; RA GEF; RA-GEF; Rap guanine nucleotide exchange factor 2; Rapgef2; RPGF2_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Anti-RAPGEF2抗體Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human RAPGEF2 (501-600aa).
●
Predicted Molecular Weight: 167kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-RAPGEF2抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
